The importance of anemia and its correction in the management of severe congestive heart failure

European Journal of Heart Failure

Volumn 4, Issue 6, 2002, Pages 681-686

  Silverberg, Donald S ^a   Wexler, Dov ^a   Iaina, Adrian ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Anemia; Congestive heart failure; Erythropoietin; Iron; Renal failure

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; IRON;

ANEMIA; CONGESTIVE HEART FAILURE; DISEASE PREDISPOSITION; DISEASE SEVERITY; HEART FUNCTION; HUMAN; HYPERTENSION; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR;

ANEMIA, IRON-DEFICIENCY; COMORBIDITY; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INCIDENCE; IRON COMPOUNDS; MALE; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036896347     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(02)00115-0     Document Type: Review

References (33)

1. Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of edema in chronic anemia: Studies of body water and sodium, renal function, haemodynamics and plasma hormones. Br Heart J 1993;70:357-62.
2. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalization. J Am Coll Cardiol 2000;35:1737-44.
3. Chatterjee B, Nydegger UE, Mohacsi P. Serum erythropoietin in heart failure patients treated with ACE inhibitors or AT1 antagonists. Eur J Heart Fail 2000;2:393-8.
4. Iverson PO, Wolbaek PR, Tonnessen T, Christensen G. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Amer J Physiol 2002;282:R166-72.
5. Tong EM, Nissenson AR. Erythropoietin and anemia. SeminNephrol 2001;21:190-203.
6. Capes SE, Gerstein HC, Negassa A, et al. Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. Diabetes Care 2000;23:377-80.
7. Vaziri ND. Erythropoietin and transferrin metabolism in nephrotic syndrome. Am J Kidney Dis 2001;38:1-8.
8. Macdougall IC. The role of ACE inhibitors and angiotensin II receptor blockers in the response to erythropoietin. Nephrol Dial Transplant 1999;14:1836-41.
9. Torre-Amione G, Bozkurt B, Deswal A, et al. An overview of tumor necrosis factor and the failing human heart. Curr Opin Cardiol 1999;14:206-10.
10. Means RT. Advances in the anemia of chronic disease. Int J Hematol 1999;70:7-12.
11. Volpe M, Tritto C, Testa U, et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic and hormonal profiles. Am J Cardiol 1994;74:468-73.
12. Kratz A, Lewandrowski KB. Normal reference laboratory values. N Engl J Med 1998;339:1063-72.
13. Wisniacki N, Aimson P, Lyle M. Is anemia a cause of heart failure in the elderly? Heart 2001;85(Suppl I):P4. (abstract).
14. Katz AM. The cardiomyopathy of overload: An unnatural growth response in the hypertrophied heart. Ann Int Med 1994;121:363-71.
15. Johnson DB, Dell'Italia LJ. Cardiac hypertrophy and failure in hypertension. Curr Opin Nephrol Hypertension 1996;5:186-91.
16. Carson JL. Morbidity risk assessment in the surgically anemic patient. Am J Surg 1995;170(Suppl 6A):32S-36S.
17. Wahr JA. Myocardial ischemia in anaemic patients. Br J Anaesth 1998;81(Suppl):10-5.
18. Goodnough LT, Bach RG. Anemia transfusion and mortality. N Engl J Med 2001;345:1272-4.
19. Wu W-C, Rathore SS, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001;345:1230-6.
20. Packer M, Cohn JN. Concensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83(Suppl 2A):1A-8.
21. Tsuyuki RT, McKelvie RJ, Arnold MO, et al. Acute precipitants of congestive heart failure exacerbations. Arch Int Med 2001;161:2337-42.
22. Al-Ahmad A, Levey A, Rand W, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;38:955-62.
23. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein JF. Anemia is associated with worse symptoms, greater impairment in functional capacity, and a significant increase in mortality in patients with advanced heart failure. J Amer Coll Cardiology 2002;39:1780-6.
24. Silverberg DS, Iaina A, Wexler D, et al. The pathological consequences of anaemia. Clin Lab Haem 2001;23:1-6.
25. Mann JFE. What are the short-term and long-term consequences of anaemia in CRF patients. Nephrol Dial Transplant 1999;14(Suppl 2):29-36.
26. Sunder-Plassmann G, Horl WH. Effect of erythropoietin on cardiovascular diseases. Am J Kidney Dis 2001;38(Suppl 1):S20-S25.
27. Besarab A, Bolton K, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New Engl J Med 1998;339:584-90.
28. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study. J Am Coll Cardiol 2001;37:1775-80.
29. Silverberg DS, Wexler D, Blum M, et al. Aggressive therapy of congestive heart failure and associated chronic renal failure with medications, and correction of anemia stops the progression of both diseases. Peritoneal Dialysis Int 2001;21(Suppl 3):236-40.
30. Cowie MR, Wood DA, Coats AJS, et al. Survival of patients with a new diagnosis of heart failure: A population-based study. Heart 2000;83:505-10.
31. Mancini D, Katz S, Lamanca J et al. Erythropoietin improves exercise capacity in patients with heart failure. Circulation 2001;17 Suppl II: Abstract.
32. Silverberg DS, Blum M, Peer G, et al. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996;72:413-7.
33. Hillege HL, Girbes ARJ, de Kam PJ, et al. Renal function neuronal activation and survival in patients with chronic heart failure. Circulation 2000;102:203-10.